Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Langsiktig oppfølgingsstudie av RGX-314 administrert i det suprakoroidale rommet for deltakere med diabetisk retinopati

5. november 2026 oppdatert av: AbbVie

En langsiktig oppfølgingsstudie for å evaluere sikkerheten og effektiviteten av suprakoroidal administrering av RGX-314 for diabetisk retinopati uten senterinvolvert-diabetisk makulært ødem

This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of DR with and without center involved-diabetic macular edema (CI-DME) in which they received suprachoroidal space (SCS) administration of ABBV-RGX-314. Enrollment of each participant in the current study should occur after the participant has completed either the end of study or early discontinuation visit in the previous (parent) clinical study. Participants will be followed for a total of 5 years post-ABBV-RGX-314 administration (inclusive of the parent study). As such, the total study duration for each participant may vary depending on when they enroll in the current study following ABBV-RGX-314 administration in the parent study.

Studieoversikt

Status

Aktiv, ikke rekrutterende

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Faktiske)

103

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Arizona
      • Phoenix, Arizona, Forente stater, 85014
        • Retinal Research Institute, LLC
    • California
      • Bakersfield, California, Forente stater, 93309
        • California Retina Consultants
      • Beverly Hills, California, Forente stater, 90211
        • Retina-Vitreous Associates Medical Group
      • Los Angeles, California, Forente stater, 90017
        • Retinal Diagnostic Center
      • Mountain View, California, Forente stater, 94040
        • Northern California Retina Vitreous Associates Medical Group Inc
      • Pasadena, California, Forente stater, 91107
        • California Eye Specialists Medical Group, Inc
      • Poway, California, Forente stater, 92064
        • Retina Consultants San Diego
      • Santa Barbara, California, Forente stater, 93103
        • California Retina Consultants CRC
    • Georgia
      • Augusta, Georgia, Forente stater, 30909
        • Southeast Retina Center, PC
    • Illinois
      • Oak Forest, Illinois, Forente stater, 60452
        • University Retina and Macula Associates, PC
    • Maryland
      • Hagerstown, Maryland, Forente stater, 21740
        • Cumberland Valley Retina Consultants
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02114
        • Ophthalmic Consultants of Boston
    • Nevada
      • Reno, Nevada, Forente stater, 89502
        • Sierra eye Associates
    • New Jersey
      • Teaneck, New Jersey, Forente stater, 07666
        • New Jersey Retina
    • New Mexico
      • Albuquerque, New Mexico, Forente stater, 87109
        • Vision Research Center Eye Associates of New Mexico
    • North Carolina
      • Durham, North Carolina, Forente stater, 27705
        • Duke University
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forente stater, 19107
        • Mid Atlantic Retina
    • Tennessee
      • Germantown, Tennessee, Forente stater, 38138
        • Charles Retina Institute, P.C
    • Texas
      • Austin, Texas, Forente stater, 78750
        • Austin Clinical Research
      • The Woodlands, Texas, Forente stater, 77384
        • Retina Consultants of Texas

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

  • Barn
  • Voksen
  • Eldre voksen

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Must provide written, signed informed consent for this study
  • Must have been enrolled in a previous clinical study of ABBV-RGX-314 for the treatment of DR with or without CI-DME and must have received an SCS injection of ABBV-RGX-314 in that study
  • Must be willing and able to comply with all study procedures

Exclusion Criteria:

  • None

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Ikke-randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Annen: Standard of Care

Dose Level (DL) 1-3 participants who received ABBV-RGX-314 in a parent study will continue to receive standard of care for the study duration.

Standard of Care

Annen: Supplemental Treatment

DL4 participants from parent study will be eligible to receive supplement aflibercept through a prespecified timepoint based on protocol-specified criteria if they develop worsening CI-DME or high-risk proliferative diabetic retinopathy (PDR) in the study eye.

Standard of Care

Injection

Andre navn:
  • EYLEA

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Incidence of ocular adverse events (AEs) and any serious adverse events (SAEs)
Tidsramme: 5 years inclusive of the parent study

To evaluate the long-term safety of ABBV-RGX-314

5 years inclusive of the parent study

Sekundære resultatmål

Resultatmål
Tidsramme
Andel deltakere som trenger ytterligere intervensjon for okulære diabetiske komplikasjoner (f.eks. anti-VEGF intravitreal injeksjon eller PRP)
Tidsramme: 5 år, inkludert foreldrestudiet
5 år, inkludert foreldrestudiet
Andel deltakere med eventuelle synstruende okulære diabetiske komplikasjoner
Tidsramme: 5 år, inkludert foreldrestudiet
5 år, inkludert foreldrestudiet
Incidences of non-ocular AEs and any Adverse Events of Special Interest
Tidsramme: 5 years, inclusive to the parent study
5 years, inclusive to the parent study
Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in DR by ETDRS-DRSS on digital stereoscopic fundus photography
Tidsramme: 5 years, inclusive of the parent study
5 years, inclusive of the parent study
Proportion of participants achieving 0-step (no change), a ≥1-step, a ≥2-step, or a ≥3-step or greater change in DR per ETDRS-DRSS on digital stereoscopic fundus photography from baseline (ie, prior to ABBV-RGX-314 administration in the parent study)
Tidsramme: 5 years, inclusive to the parent study
5 years, inclusive to the parent study
Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in BCVA
Tidsramme: 5 years, inclusive to the parent study
5 years, inclusive to the parent study
Proportion of participants gaining or losing ≥ 5, 10, and 15 letters in BCVA compared with baseline (ie, prior to ABBV-RGX-314 administration in the parent study)
Tidsramme: 5 years, inclusive to the parent study
5 years, inclusive to the parent study
Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in CST as measured by SD-OCT
Tidsramme: 5 years, inclusive to the parent study
5 years, inclusive to the parent study
Mean change from baseline (ie, prior to ABBV-RGX-314 administration in the parent study) in the area of retinal nonperfusion on ultra-widefield Optos FA
Tidsramme: 5 years, inclusive to the parent study
5 years, inclusive to the parent study
Mean number of anti-VEGF injections through years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)
Tidsramme: 5 years, inclusive to the parent study
5 years, inclusive to the parent study
Mean number of anti-VEGF injections in years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)
Tidsramme: 5 years, inclusive to the parent study
5 years, inclusive to the parent study
Mean anti-VEGF injection annualized rate through years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)
Tidsramme: 5 years, inclusive to the parent study
5 years, inclusive to the parent study
Mean anti-VEGF injection annualized rate in years 2, 3, 4, and 5 based on ongoing chart review in the study eye (DL4 participants only)
Tidsramme: 5 years, inclusive to the parent study
5 years, inclusive to the parent study
Mean number of retina specialist visits attended for complications of DR based on chart review
Tidsramme: 5 years, inclusive to the parent study
5 years, inclusive to the parent study

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

4. april 2022

Primær fullføring (Antatt)

1. juni 2031

Studiet fullført (Antatt)

1. juni 2031

Datoer for studieregistrering

Først innsendt

16. mars 2022

Først innsendt som oppfylte QC-kriteriene

16. mars 2022

Først lagt ut (Faktiske)

25. mars 2022

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

6. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

5. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • RGX-314-5201 (M23-420)
  • M23-420 (Annen identifikator: AbbVie Inc)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

IPD-delingstidsramme

For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/

Tilgangskriterier for IPD-deling

To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .